OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally.
Oncocyte stock last closed at $2.39, down 4.4% from the previous day, and has decreased 20.6% in one year. It has overperformed other stocks in the Diagnostics & Research industry by 0.07 percentage points. Oncocyte stock is currently +20.71% from its 52-week low of $1.98, and -37.43% from its 52-week high of $3.82.
At the moment, there are 16.84M OCX shares outstanding. The market value of OCX is $40.24M. In the past 24 hours, 13,478 OCX shares were traded.
How to Buy Oncocyte Stock
Wondering how to invest in Oncocyte stock? Here's how.
Choose where to buy Oncocyte stock: You need to decide on a stock brokerage, but don't worry - we've tested dozens of stock brokerages and apps to help you decide where to buy Oncocyte stock.
Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
Put funds into your brokerage account: Select your method of payment and add your info.
Analyze Oncocyte stock: The Oncocyte ticker symbol is OCX. Is Oncocyte stock a good investment? Should you buy shares of OCX? How do OCX's underlying business fundamentals look? Do top analysts think Oncocyte is a good buy? Why has OCX's stock price moved recently? (Hint: Our stock market research tools can help you understand if OCX is a good stock to buy).
Execute your OCX buy order: Decide if you will purchase OCX shares at the current market price or use a limit order to buy OCX shares at a given price.
Get updates on your investment in OCX: Create a watchlist to keep track of your position in Oncocyte stock.
Step 1: Choose where to buy Oncocyte stock
You need an online brokerage account to access the NASDAQ market and buy OCX shares.
A brokerage account enables you to buy and sell a number of financial instruments, such as stocks, bonds, mutual funds, and ETFs.
Our preferred brokerage: eToro
In our opinion, eToro is the best place to buy stocks. Here's why:
You can invest in stocks with 0% commissions: Invest without commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
Access to world financial markets: From Technology to Utilities, New York to Shanghai — you can fill your portfolio with stocks from the globe's leading stock exchanges.
Social investing: eToro boasts a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by creating an account with eToro now.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Sign up for your brokerage account
Now that you've picked the best brokerage, you'll need to fill out some personal information so you are able to buy OCX today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Analyze Oncocyte stock
Once you have figured out the best place to buy Oncocyte stock, it's absolutely critical to research their stock before you invest, so you actually wrap your head around the risk as well as the upside.
Oncocyte stock quick numbers
OCX Price
$2.39
1w %
0%
1y %
-20.6%
5y %
-93.87%
P/E
0x
P/B
4.14x
P/S
45.96x
PEG
N/A
Revenue
$709.00k
Earnings
-$43.55M
Fore. Rev. Growth
309.03%
Fore. Earn. Growth
N/A
Market Cap
$40.24M
Next Earnings
N/A
Next Dividend
N/A
Oncocyte Due Diligence Score
WallStreetZen was designed to help average investors perform more accurate fundamental analysis in less time.
You can see all of the due diligence checks on OCX's stock page.
Is OCX stock properly valued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge OCX's intrinsic value.
Using relative valuations measures:
OCX could be overvalued based on its P/B ratio of 4.14x, relative to Diagnostics & Research industry P/B ratio of 4.08x
Last year, OCX revenue was $709.00k. In the past 4 year, OCX's revenue has grown by -0.18% per year. This was slower than the Diagnostics & Research industry average of 9.79%.
No, Oncocyte doesn't provide an income stream by paying out dividends.
Get analysis from other investors
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Execute your OCX buy order
You have two primary order types:
Market order: A market order is an order to buy or sell a security at the best possible price. Market orders are generally the best for newer investors.
Limit order: A limit order lets you buy or sell a security at a specific price (or better). If you want to be certain you're buying or selling at an exact price, use a limit order.
Press the Open Trade button and eToro will execute your order.
If you require more help buying stocks on eToro, click the helpful video below:
As of Dec 11, 2024, it costs $2.39 to buy one share of Oncocyte stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $1, you can buy 0.418 shares of OCX.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.